Non-valvular atrial fibrillation in patients on peritoneal dialysis, prevalence, treatment and professionals involved
Copyright © 2024. Published by Elsevier España, S.L.U..
Atrial fibrillation is the most frequent chronic arrhythmia in patients with chronic kidney disease. Oral anticoagulation with vitamin K antagonists and now direct oral anticoagulants have been and are the fundamental pillars for the prevention of thromboembolic events. However, there are no randomized clinical trials on the risk-benefit profile of oral anticoagulation in patients with chronic kidney disease stage 5 on peritoneal dialysis and there is little evidence in the literature in this population. The objective of our study was to know the prevalence, treatment and professionals involved in the management of atrial fibrillation in peritoneal dialysis patients. For this purpose, we performed a descriptive analysis through a survey sent to different peritoneal dialysis units in Spain. A total of 1,403 patients on peritoneal dialysis were included in the study, of whom 186 (13.2%) had non-valvular atrial fibrillation. In addition, the assessment of the scores of thromboembolic and bleeding risks for the indication of oral anticoagulation was mainly carried out by the cardiologist (60% of the units), as well as its prescription (cardiologist 47% or in consensus with the nephrologist 43%). In summary, patients on peritoneal dialysis have a remarkable prevalence of non-valvular atrial fibrillation. Patients frequently receive oral anticoagulation with vitamin K antagonists, as well as direct oral anticoagulants. The data obtained regarding the scores used for the assessment of thromboembolic and bleeding risk, treatment and involvement by Nephrology indicates that there is a need for training and involvement of the nephrologist in this pathology.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
Nefrologia - 44(2024), 2 vom: 10. März, Seite 268-275 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Perez-Bernat, Elisa [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 02.05.2024 Date Revised 06.05.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.nefroe.2024.03.008 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370990706 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370990706 | ||
| 003 | DE-627 | ||
| 005 | 20240507232510.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240413s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.nefroe.2024.03.008 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1400.xml |
| 035 | |a (DE-627)NLM370990706 | ||
| 035 | |a (NLM)38609756 | ||
| 035 | |a (PII)S2013-2514(24)00066-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Perez-Bernat, Elisa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Non-valvular atrial fibrillation in patients on peritoneal dialysis, prevalence, treatment and professionals involved |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.05.2024 | ||
| 500 | |a Date Revised 06.05.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024. Published by Elsevier España, S.L.U. | ||
| 520 | |a Atrial fibrillation is the most frequent chronic arrhythmia in patients with chronic kidney disease. Oral anticoagulation with vitamin K antagonists and now direct oral anticoagulants have been and are the fundamental pillars for the prevention of thromboembolic events. However, there are no randomized clinical trials on the risk-benefit profile of oral anticoagulation in patients with chronic kidney disease stage 5 on peritoneal dialysis and there is little evidence in the literature in this population. The objective of our study was to know the prevalence, treatment and professionals involved in the management of atrial fibrillation in peritoneal dialysis patients. For this purpose, we performed a descriptive analysis through a survey sent to different peritoneal dialysis units in Spain. A total of 1,403 patients on peritoneal dialysis were included in the study, of whom 186 (13.2%) had non-valvular atrial fibrillation. In addition, the assessment of the scores of thromboembolic and bleeding risks for the indication of oral anticoagulation was mainly carried out by the cardiologist (60% of the units), as well as its prescription (cardiologist 47% or in consensus with the nephrologist 43%). In summary, patients on peritoneal dialysis have a remarkable prevalence of non-valvular atrial fibrillation. Patients frequently receive oral anticoagulation with vitamin K antagonists, as well as direct oral anticoagulants. The data obtained regarding the scores used for the assessment of thromboembolic and bleeding risk, treatment and involvement by Nephrology indicates that there is a need for training and involvement of the nephrologist in this pathology | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antagonistas de la vitamina K | |
| 650 | 4 | |a Antiagregación | |
| 650 | 4 | |a Anticoagulación oral | |
| 650 | 4 | |a Anticoagulantes orales de acción directa | |
| 650 | 4 | |a Antiplatelet agents | |
| 650 | 4 | |a Atrial fibrillation | |
| 650 | 4 | |a Direct oral anticoagulants | |
| 650 | 4 | |a Diálisis peritoneal | |
| 650 | 4 | |a Fibrilación auricular | |
| 650 | 4 | |a Oral anticoagulation | |
| 650 | 4 | |a Peritoneal dialysis | |
| 650 | 4 | |a Vitamin K antagonists | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 700 | 1 | |a Viñas, M ª Angeles |e verfasserin |4 aut | |
| 700 | 1 | |a Vera, Manel |e verfasserin |4 aut | |
| 700 | 1 | |a González-Rico, Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Montomoli, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Astudillo-Cortés, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Quevedo-Reina, Juan Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a García-Méndez, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Martinez-Losa, Adoración |e verfasserin |4 aut | |
| 700 | 1 | |a Rama-Arias, Ines |e verfasserin |4 aut | |
| 700 | 1 | |a Maldonado-Martín, María |e verfasserin |4 aut | |
| 700 | 1 | |a Munar, M ª Antonia |e verfasserin |4 aut | |
| 700 | 1 | |a Cerrato, Agustín Ortega |e verfasserin |4 aut | |
| 700 | 1 | |a Beltrán-Catalán, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Peso, Gloria Del |e verfasserin |4 aut | |
| 700 | 1 | |a Cases, Aleix |e verfasserin |4 aut | |
| 700 | 1 | |a Górriz, Jose Luis |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nefrologia |d 2018 |g 44(2024), 2 vom: 10. März, Seite 268-275 |w (DE-627)NLM270991409 |x 2013-2514 |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2024 |g number:2 |g day:10 |g month:03 |g pages:268-275 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.nefroe.2024.03.008 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2024 |e 2 |b 10 |c 03 |h 268-275 | ||